PARTNER NEWS:Fri, Apr 12, 11:55 AM, Zacks
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Fri, Feb 23, 8:55 AM, Zacks
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High? The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Featured MNV Articles: COMPASS Pathways (CMPS) Shares Cross Below 200 DMA
Thursday, April 18, 4:58 PM ET, by Market News Video Staff
In trading on Thursday, shares of COMPASS Pathways plc (CMPS) crossed below their 200 day ...
AnaptysBio Breaks Below 200-Day Moving Average - Notable for ANAB
Thursday, April 18, 4:56 PM ET, by Market News Video Staff
In trading on Thursday, shares of AnaptysBio Inc (ANAB) crossed below their 200 day moving ...
Notable Two Hundred Day Moving Average Cross - CERT
Thursday, April 18, 4:56 PM ET, by Market News Video Staff
In trading on Thursday, shares of Certara Inc (CERT) crossed below their 200 day moving ...
WhiteHorse Finance Breaks Above 200-Day Moving Average - Bullish for WHF
Thursday, April 18, 4:46 PM ET, by Market News Video Staff
In trading on Thursday, shares of WhiteHorse Finance Inc. (WHF) crossed above their 200 day ...
RBC Bearings Enters Oversold Territory
Thursday, April 18, 4:45 PM ET, by Market News Video Staff
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...
|
|
By Dividend Channel Staff, Wednesday, December 31, 7:00 PM ET
|